{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062474","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.093536+00:00","generated_at":"2026-06-08T04:52:05.219728+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acasti Q2 FY2024 net loss falls to $3.3M; first patient dosed in pivotal GTX-104 trial","bullets":["Net loss of $3.3M ($0.43/share) vs $5.0M ($0.66/share) in Q2 FY2023; R&D spending cut to $0.4M.","Cash and cash equivalents $27.0M at Sep 30, 2023, down $0.9M from Mar 31, 2023; $7.5M private placement closed in Sep 2023.","First patient enrolled in STRIVE-ON Phase 3 trial of GTX-104 for aneurysmal subarachnoid hemorrhage (aSAH).","GTX-104 NDA submission to FDA on track for first half of 2025.","Private placement led by ADAR1 Partners; proceeds to fund Phase 3 trial, NDA prep, and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062474","json":"https://secwatch.observer/filing/0000950170-23-062474.json","markdown":"https://secwatch.observer/filing/0000950170-23-062474.md","text":"https://secwatch.observer/filing/0000950170-23-062474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023062474/0000950170-23-062474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023062474/acst-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:52:05.219728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f41931cb730071fdfc5eab84cdb048ea9d25d65a","claim":"Grace Therapeutics, Inc. reported three months ended September 30, 2023 results: net income Net loss $3.3 million or $0.43 per share, EPS $0.43 per share.","evidence_excerpt":"Net loss $3.3 million or $0.43 per share for the three months ended September 30, 2023 decreased by $1.7 million from the net loss of $5.0 million or $0.66 per share for the three months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023062474/0000950170-23-062474-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Net income","value":"Net loss $3.3 million or $0.43 per share"},{"label":"EPS","value":"$0.43 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}